Annandale Capital, LLC Aadi Bioscience, Inc. Transaction History
Annandale Capital, LLC
- $543 Million
- Q1 2024
Shares
2 transactions
Others Institutions Holding AADI
# of Institutions
64Shares Held
13.7MCall Options Held
4.9KPut Options Held
700-
Avoro Capital Advisors LLC New York, NY2.85MShares$4.16 Million0.08% of portfolio
-
Acuta Capital Partners, LLC Belmont, CA1.85MShares$2.7 Million3.54% of portfolio
-
Satter Management Co., L.P.1.63MShares$2.38 Million4.26% of portfolio
-
Black Rock Inc. New York, NY1.04MShares$1.52 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA857KShares$1.25 Million0.0% of portfolio
About Aadi Bioscience, Inc.
- Ticker AADI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 21,016,800
- Market Cap $30.7M
- Description
- Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, ...